News | September 23, 2024
AstraZeneca Pharma India to launch Tremelimumab
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
The clinical trial will be conducted at 19 sites with 10,335 participants across India
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
MedTech Mitra is a platform that will help the young talents of the country by holding their hands and giving them final shape to their research, knowledge and logic
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
Subscribe To Our Newsletter & Stay Updated
